{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:15:34Z","timestamp":1773296134110,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP 119473"],"award-info":[{"award-number":["MOP 119473"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004089","name":"Krembil Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004089","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pan-Provincial Vaccine Enterprise"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.vaccine.2015.01.041","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T15:50:21Z","timestamp":1422460221000},"page":"1338-1344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies"],"prefix":"10.1016","volume":"33","author":[{"given":"R.","family":"Garg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Latimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gerdts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"van Drunen Littel-van den Hurk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.01.041_bib0110","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0115","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","author":"Group TI-RS","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0125","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1128\/JVI.01625-07","article-title":"Viral and host factors in human respiratory syncytial virus pathogenesis","volume":"82","author":"Collins","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0264-410X(92)90027-H","article-title":"Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb\/c mice","volume":"10","author":"Vaux-Peretz","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0135","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1016\/j.vaccine.2012.06.011","article-title":"Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles","volume":"30","author":"Garlapati","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1099\/vir.0.058461-0","article-title":"Induction of mucosal immunity and protection by intranasal immunisation with a novel respiratory syncytial virus vaccine formulation","volume":"95","author":"Garg","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0145","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1099\/vir.0.062570-0","article-title":"Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity","volume":"95","author":"Garg","year":"2014","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0150","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3390\/v4102359","article-title":"Perinatal lamb model of respiratory syncytial virus (RSV) infection","volume":"4","author":"Derscheid","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0155","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1099\/0022-1317-81-11-2665","article-title":"The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon","volume":"81","author":"Raggo","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0160","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ilar\/ilu003","article-title":"Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments","volume":"55","author":"Ackermann","year":"2014","journal-title":"Ilar J"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/17425247.3.1.87","article-title":"Noninvasive delivery technologies: respiratory delivery of vaccines","volume":"3","author":"Sullivan","year":"2006","journal-title":"Expert Opin Drug Delivery"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0175","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/j.vaccine.2010.01.018","article-title":"Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens","volume":"28","author":"Vujanic","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0180","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/mi.2008.59","article-title":"Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing","volume":"1","author":"Wee","year":"2008","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0185","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.vaccine.2005.08.051","article-title":"Report of a consultation on role of immunological assays to evaluate efficacy of influenza vaccines. Initiative for Vaccine Research and Global Influenza Programme, World Health Organization, Geneva, Switzerland, 25 January 2005","volume":"24","author":"Cassetti","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/infdis\/174.2.256","article-title":"Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection","volume":"174","author":"Weltzin","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0195","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/JCM.26.8.1595-1597.1988","article-title":"Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity","volume":"26","author":"Murphy","year":"1988","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0200","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0264-410X(98)00103-0","article-title":"Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines","volume":"16","author":"Crowe","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0205","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1086\/512615","article-title":"Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses","volume":"195","author":"Welliver","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.041_bib0210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/modpathol.3800725","article-title":"The histopathology of fatal untreated human respiratory syncytial virus infection","volume":"20","author":"Johnson","year":"2007","journal-title":"Mod Pathol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T11:52:28Z","timestamp":1598701948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0264410X15000857"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.041","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}